# US 2003/0225288 A1 · Imidazolidine compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0225288 A1
- Document ID: US20030225288A1
- Status: Published application
- Kind: A1
- Application number: 10/123,027
- Filed: 2002-04-12
- Published: 2003-12-04
- Earliest claimed: 2002-04-12
- Assignees: Millennium Pharmaceuticals, Inc.; Kyowa Hakko Kogyo Co., Ltd.
- Inventors: Etsuo Ohshima; Hiroki Sone; Osamu Kotera; Jay R. Luly; Gregory J. LaRosa
- Web page: https://patentgrep.com/patent/US20030225288A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 233/26: Radicals substituted by carbon atoms having three bonds to hetero atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are novel compounds and a method of treating inflammatory diseases. The method comprises administering to an individual in need an effective amount of an imidazolidine compound represented by Structural Formula (I): 1 or a physiologically acceptable salt thereof.

## Claims

### Claim 1

An imidazolidine compound represented by the following Formula (I):
111
or a physiologically acceptable salt thereof, wherein:
Z is
hydrogen,
halogen,
hydroxy,
—COOH,
—CONH2,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted haloalkyl,
substituted or unsubstituted heteroalkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted polycycloalkyl,
substituted or unsubstituted lower alkenyl,
substituted or unsubstituted cycloalkenyl,
substituted or unsubstituted polycycloalkenyl,
substituted or unsubstituted lower alkoxy,
substituted or unsubstituted lower alkanoyloxy,
substituted or unsubstituted lower alkanoyl,
substituted or unsubstituted lower alkoxycarbonyl,
substituted or unsubstituted aralkyl,
substituted or unsubstituted heteroaralkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, or
a substituted or unsubstituted non-aromatic heterocyclic group, or
Z and R6 taken together form a bond, or
Z and R13a taken together form a bond;
X1 and X2 are each, independently,
hydrogen,
—CN,
—NO2,
—SO2R15a,
—SO2NR15aR15b,
—C(═O)—R15a,
—C(═O)—OR15a, or
—C(═O)—NR15aR15b, wherein
R15a and R15b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl, or
substituted or unsubstituted aralkyl;
Y is
a bond,
—(C═O)—, or
—(CR16aR16b)—, wherein
R16a and R16b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl, or
substituted or unsubstituted aralkyl;
R1 is
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted polycycloalkyl,
substituted or unsubstituted lower alkenyl,
substituted or unsubstituted cycloalkenyl,
substituted or unsubstituted lower alkoxy,
substituted or unsubstituted lower alkanoyloxy,
substituted or unsubstituted aralkyl,
substituted or unsubstituted heteroaralkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, or
a substituted or unsubstituted non-aromatic heterocyclic group;
R2a, R2b, R3a, R3b, R4a, R4b, R5a, and R5b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted aralkyl, or
substituted or unsubstituted heteroaralkyl;
R6, R7, R8, and R9 are each, independently,
hydrogen,
hydroxy,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted lower alkoxy,
substituted or unsubstituted lower alkanoyl,
substituted or unsubstituted lower alkanoyloxy,
substituted or unsubstituted lower alkoxycarbonyl,
substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl,
halogen,
—CN,
—NO2,
—C(═O) OR17a,
—NR17aR17b, or
—C(═O)—NR17aR17b, wherein
R17a and R17b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl, or
substituted or unsubstituted aralkyl, or
R17a and R17b taken together with the nitrogen atom to which they are bonded form a substituted or unsubstituted heterocyclic group containing at least one nitrogen atom;
R10a, R10b, R11a, and R11b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted aralkyl,
substituted or unsubstituted heteroaralkyl, or
substituted or unsubstituted lower alkoxyalkyl;
R12a and R12b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted aralkyl, or
substituted or unsubstituted heteroaralkyl, or
R12a and R12b taken together with the nitrogen atom to which they are bonded form a substituted or unsubstituted heterocyclic group containing at least one nitrogen atom;
R13a and R13b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted aralkyl, or
substituted or unsubstituted heteroaralkyl,
wherein when p is 2 or more, multiple R13a's are independently the same or different and multiple R13b's are independently the same or different;
m is an integer from 0 to 4;
n is an integer from 0 to 6;
p is an integer from 0 to 9; and
q is an integer from 0 to 5

### Claim 2 (depends on 1)

The imidazolidine compound according to claim 1 wherein
Z is
hydrogen,
halogen,
hydroxy,
COOH,
CONH2,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted haloalkyl,
substituted or unsubstituted heteroalkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted lower alkenyl,
substituted or unsubstituted lower alkoxy,
substituted or unsubstituted lower alkanoyloxy,
substituted or unsubstituted lower alkanoyl,
substituted or unsubstituted lower alkoxycarbonyl,
substituted or unsubstituted aralkyl,
substituted or unsubstituted heteroaralkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, or
a substituted or unsubstituted non-aromatic heterocyclic group, or
Z and R6 taken together form a bond, or
Z and R13a taken together form a bond;
X1 and X2 are each, independently,
hydrogen,
—CN,
—NO2,
—C(═O)—R15a,
—C(═O)—OR15a, or
—C(═O)—NR15aR15b, wherein
R15a and R15b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl, or
substituted or unsubstituted aralkyl;
R6, R7, R8, and R9 are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted lower alkoxy,
substituted or unsubstituted lower alkanoyl,
substituted or unsubstituted lower alkoxycarbonyl,
substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl,
halogen,
—CN,
—NO2,
—C(═O)—OR17a,
—NR17aR17b, or
—C(═O)—NR17aR17b, wherein
R17a and R17b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl, or
substituted or unsubstituted aralkyl, or
R17a and R17b taken together with the nitrogen atom to which they are bonded form a substituted or unsubstituted heterocyclic group containing at least one nitrogen atom;
m is an integer from 0 to 3;
n is an integer from 0 to 3;
p is an integer from 0 to 8; and
q is an integer from 0 to 3.

### Claim 3 (depends on 2)

The imidazolidine compound according to claim 2 wherein
X1 and X2 are each, independently,
hydrogen,
—CN, or
—NO2;
R1 is
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted lower alkenyl,
substituted or unsubstituted lower alkoxy,
substituted or unsubstituted lower alkanoyloxy,
substituted or unsubstituted aralkyl,
substituted or unsubstituted heteroaralkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, or
a substituted or unsubstituted non-aromatic heterocyclic group;
R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl, or
substituted or unsubstituted aralkyl;
R6, R7, R8, and R9 are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted lower alkoxy,
substituted or unsubstituted heteroaryl,
halogen,
—CN, or
—NO2:
R10a, R10b, R11a, and R11b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl, or
substituted or unsubstituted aryl.

### Claim 4 (depends on 1)

A composition comprising the imidazolidine compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

### Claim 5

A method of inhibiting inflammation in an individual, comprising administering to the individual a therapeutically effective amount of an imidazolidine compound represented by the following Formula (I):
112
or a physiologically acceptable salt thereof, wherein:
Z is
hydrogen,
halogen,
hydroxy,
—COOH,
—CONH2,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted haloalkyl,
substituted or unsubstituted heteroalkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted polycycloalkyl,
substituted or unsubstituted lower alkenyl,
substituted or unsubstituted cycloalkenyl,
substituted or unsubstituted polycycloalkenyl,
substituted or unsubstituted lower alkoxy,
substituted or unsubstituted lower alkanoyloxy,
substituted or unsubstituted lower alkanoyl,
substituted or unsubstituted lower alkoxycarbonyl,
substituted or unsubstituted aralkyl,
substituted or unsubstituted heteroaralkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, or
a substituted or unsubstituted non-aromatic heterocyclic group, or
Z and R6 taken together form a bond, or
Z and R13a taken together form a bond;
X1 and X2 are each, independently,
hydrogen,
—CN,
—NO2,
—SO2R15a,
—SO2NR15aR15b,
—C(═O)—R15a,
—C(═O)—OR15a, or
—C(═O)—NR15aR15b, wherein
R15a and R15b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl, or
substituted or unsubstituted aralkyl;
Y is
a bond,
—(C═O)—, or
—(CR16aR16b)—, wherein
R16a and R16b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl, or
substituted or unsubstituted aralkyl;
R1 is
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted polycycloalkyl,
substituted or unsubstituted lower alkenyl,
substituted or unsubstituted cycloalkenyl,
substituted or unsubstituted lower alkoxy,
substituted or unsubstituted lower alkanoyloxy,
substituted or unsubstituted aralkyl,
substituted or unsubstituted heteroaralkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, or
a substituted or unsubstituted non-aromatic heterocyclic group;
R2aR2bR3aR3bR4aR4b, R5a and R5b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted aralkyl, or
substituted or unsubstituted heteroaralkyl;
R6, R7, R8, and R9 are each, independently,
hydrogen,
hydroxy,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted lower alkoxy,
substituted or unsubstituted lower alkanoyl,
substituted or unsubstituted lower alkanoyloxy,
substituted or unsubstituted lower alkoxycarbonyl,
substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl,
halogen,
—CN,
—NO2,
—C(═O)—OR17a,
—NR17aR17b, or
—C(═O)—NR17aR17b, wherein
R17a and R17b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl, or
substituted or unsubstituted aralkyl, or
R17a and R17b taken together with the nitrogen atom to which they are bonded form a substituted or unsubstituted heterocyclic group containing at least one nitrogen atom;
R10a, R10b, R11a, and R11b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted aralkyl,
substituted or unsubstituted heteroaralkyl, or
substituted or unsubstituted lower alkoxyalkyl;
R12a and R12b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted aralkyl, or
substituted or unsubstituted heteroaralkyl, or
R12a and R12b taken together with the nitrogen atom to which they are bonded form a substituted or unsubstituted heterocyclic group containing at least one nitrogen atom;
R13a and R13b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted aralkyl, or
substituted or unsubstituted heteroaralkyl,
wherein when p is 2 or more, multiple R13a's are independently the same or different and multiple R13b's are independently the same or different;
m is an integer from 0 to 4;
n is an integer from 0 to 6;
p is an integer from 0 to 9; and
q is an integer from 0 to 5

### Claim 6 (depends on 5)

The method according to claim 5 wherein said inflammation is a consequence of an autoimmune disease.

### Claim 7 (depends on 5)

The method according to claim 5 wherein said inflammation is a consequence of an allergic disease or condition.

### Claim 8 (depends on 5)

The method according to claim 5 wherein said inflammation is a consequence of infection.

### Claim 9 (depends on 8)

The method according to claim 8 wherein said infection is bacterial, viral, fungal or parasitic.

### Claim 10

A method of treating an individual having a disease associated with pathogenic leukocyte recruitment and/or activation, comprising administering to the individual a therapeutically effective amount of an imidazolidine compound represented by the following Formula (I):
113
or a physiologically acceptable salt thereof, wherein
Z is
hydrogen,
halogen,
hydroxy,
—COOH,
—CONH2,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted haloalkyl,
substituted or unsubstituted heteroalkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted polycycloalkyl,
substituted or unsubstituted lower alkenyl,
substituted or unsubstituted cycloalkenyl,
substituted or unsubstituted polycycloalkenyl,
substituted or unsubstituted lower alkoxy,
substituted or unsubstituted lower alkanoyloxy,
substituted or unsubstituted lower alkanoyl,
substituted or unsubstituted lower alkoxycarbonyl,
substituted or unsubstituted aralkyl,
substituted or unsubstituted heteroaralkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, or
a substituted or unsubstituted non-aromatic heterocyclic group, or
Z and R6 taken together form a bond, or
Z and R13a taken together form a bond;
X1 and X2 are each, independently,
hydrogen,
—CN,
—NO2,
—SO2R15a,
—SO2NR15aR15b,
—C(═O)—R15a,
—C(═O)—OR15a, or
—C(═O)—NR15aR15b, wherein
R15a and R15b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl, or
substituted or unsubstituted aralkyl;
Y is
a bond,
—(C═O)—, or
(CR16aR16b)—, wherein
R16a and R16b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl, or
substituted or unsubstituted aralkyl;
R1 is
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted polycycloalkyl,
substituted or unsubstituted lower alkenyl,
substituted or unsubstituted cycloalkenyl,
substituted or unsubstituted lower alkoxy,
substituted or unsubstituted lower alkanoyloxy,
substituted or unsubstituted aralkyl,
substituted or unsubstituted heteroaralkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl, or
a substituted or unsubstituted non-aromatic heterocyclic group;
R2a, R2b, R3a, R3b, R4a, R4b, R5a, and R5b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted aralkyl, or
substituted or unsubstituted heteroaralkyl;
R6, R7, R8, and R9 are each, independently,
hydrogen,
hydroxy,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted lower alkoxy,
substituted or unsubstituted lower alkanoyl,
substituted or unsubstituted lower alkanoyloxy,
substituted or unsubstituted lower alkoxycarbonyl,
substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl,
halogen,
—CN, —C(═O)—OR17a,
—NR17aR17a, or
—C(═O)—NR17aR17b, wherein
R17a and R17b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl, or
substituted or unsubstituted aralkyl, or
R17a and R17b taken together with the nitrogen atom to which they are bonded form a substituted or unsubstituted heterocyclic group containing at least one nitrogen atom;
R10a, R10b, R11a, and R11b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted aralkyl,
substituted or unsubstituted heteroaralkyl, or
substituted or unsubstituted lower alkoxyalkyl;
R12a and R12b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted aralkyl, or
substituted or unsubstituted heteroaralkyl, or
R12a and R12b taken together with the nitrogen atom to which they are bonded form a substituted or unsubstituted heterocyclic group containing at least one nitrogen atom;
R13a and R13b are each, independently,
hydrogen,
substituted or unsubstituted lower alkyl,
substituted or unsubstituted cycloalkyl,
substituted or unsubstituted aryl,
substituted or unsubstituted aralkyl, or
substituted or unsubstituted heteroaralkyl,
wherein when p is 2 or more, multiple R13a's are independently the same or different and multiple R13b's are independently the same or different;
m is an integer from 0 to 4;
n is an integer from 0 to 6;
p is an integer from 0 to 9; and
q is an integer from 0 to 5

### Claim 11 (depends on 10)

The method according to claim 10, wherein said disease is an autoimmune disease.

### Claim 12 (depends on 10)

The method according to claim 10, wherein said disease is an allergic disease or condition.
